How Robots Will Transform the C-Suite
Senior executives need to lead a workforce that seamlessly blends human talent and automation. Visit strategy+business to read more.
Zdravotnictví a farmacie
Komplexní servis pod jednou střechou
Farmaceutický průmysl v České republice z velké části ovládají zahraniční vlastníci. Farmaceutické společnosti se pohybují v prostředí nesmírně přísné a komplexní regulace: Státní ústav pro kontrolu léčiv reguluje všechny aspekty tohoto podnikání – od tvorby cen po balení, od klinických zkoušek po reklamu.
Odborníci PwC na farmaceutický průmysl patří k předním specialistům na tento obor v zemi a dokáží vám dobře poradit s daňovými, právními a regulačními otázkami tohoto odvětví.
Aktuální problémy
- Omezené marže dané státní regulací cen léků
- Potřeba alternativního financování operací, které může vést ke vzniku struktur rizikových z hlediska dodržování pravidel cenové regulace
- Regulace reklamy, která se vztahuje i na sponzoring, dárky, vzorky léčiv atd.
- Regulace distribuce léků
- Ochrana duševního vlastnictví
- Návratnost investic do výzkumu a vývoje
- Rychlé šíření licenčních ujednání a společného uvádění léků na trh
Služby specifické pro toto odvětví
- Daňové poradenství ve vztahu k registraci léků a klinickým zkouškám
- Poradenství o daňovém řešení poskytování vzorků, dárků a slev, včetně slev „v naturáliích“
- Služby související s plněním regulačních požadavků a řízením rizika
- Studie o odměňování PayWell pro farmaceutický průmysl
- Urovnání, arbitráže a soudní řízení u sporů pro porušení patentu, o náhradu následných škod či pro porušení smlouvy, sporů o záruky a sporů souvisejících se stavbami
- Pomoc při stažení výrobku z trhu (z legislativních, zdravotních, bezpečnostních či obchodních důvodů nebo pro porušení licenčních ujednání) a řešení všech souvisejících nároků
- Posouzení souladu s licenčními a jinými obchodními ujednáními a poradenství ohledně vhodných postupů pro řízení plateb a příjmu licenčních poplatků
Publikace*
New dynamics of the pharmaceutical oncology market
Amid projected growth, the pharmaceutical oncology market is undergoing significant change.
Global Pharma and Life Sciences deals insights: Year-end 2018
In Q4 2018 deal volume declined after two quarters of increases. Deal value continues to fluctuate depending on the presence of megadeals.
Global top health industry issues: Defining the healthcare of the future
More connected and consumer-oriented than ever before, the world’s health systems are challenged to build resiliency in times of change.
US tax reform: Implications for pharma and life sciences
US Tax Reform will impact both US and non-US Pharma companies. This PwC presentation examines some of the main provisions.
Riding the wave of data: Transforming the future of biopharma R&D
Overcoming challenges and unlocking value from data to shape the future of R&D using data and analytics.
Predicting patient health using blockhain and wearable technology
Wearable technology has taken the world by storm over the past number of years. Members of the public have been liberated, finally able to take control over their health, wellbeing and lifestyle. More so now than ever, lifestyle has become a major factor in the success of many sectors
Under lock and key. How Blockchain secures controlled drugs
Controlled drugs are heavily regulated across the healthcare sector. They are drugs controlled under the Misuse of Drugs regulations 2001, that are open to abuse, misuse, illegal activity or can cause harm, i.e. morphine. Why is regulation important?
IFRS - Issues and solutions for the pharmaceuticals and life sciences industry - 2017 edition
PwC’s insight on how to apply IFRS in common pharmaceuticals and life sciences transactions, including guidance on the new revenue standard, IFRS 15.
2017 Pharmaceuticals and Life Sciences Trends
The New Health Economy is inspiring fresh ways to manage data, place a value on medical treatments, and deal with empowered patients.
Introducing the Pharma 2020 series
PwC's Pharma 2020 series reports look into the future of the Pharmaceuticals and Life Sciences’ value chain, and they include an analysis of the strategies needed to compete successfully in the future.
Pharma 2020: Supplying the future -- Which path will you take?
PwC's report discusses how pharma companies must develop different supply chain models for different product types and patient segments, use their supply chains for market differentiation and see the role information plays to drive the flow of products and services.
Pharma 2020: Taxing times ahead
The fifth report in the series, it focusses on the opportunities and challenges from a tax perspective. It discusses how the political, economic, scientific and social trends currently shaping the commercial environment, together with the development of new, more collaborative business models, will exert increasing pressure on effective tax rates within the industry. It also shows how companies can adapt their strategies to support the provision of outcomes-based healthcare and remain competitive.
Pharma 2020: Challenging business models - Which path will you take?
Pharma 2020: Challenging business models - Which path will you take?
Pharma 2020: Marketing the future - Which path will you take?
This paper discusses how the industry is no longer being rewarded for incremental innovation, me-too products and selling the most pills. Companies need to add value to patients, and offer a package of products and health services that the market is willing to pay a premium for.
Pharma and Life Sciences Tax News - Vol 7, No. 10: IRS Identifies Factors for Determining Deductibility of Settlement Payments
Few tax issues are more fact-intensive than determining the tax consequences to the payor of payments made under a settlement agreement with a governmental body when the agreement is silent as to the nature of the payments. In a legal advice memorandum, the IRS Office of Chief Counsel shed some light on the factors it thinks are important in such a situation. Whenever possible, of course, the taxpayer should seek to negotiate settlement agreement terms that would support the desired tax treatment.
Pharma 2020: Virtual R&D
Pharma 2020: Virtual R&D explores how pharma companies could dramatically improve the R&D productivity. It contents that by 2020 the R&D process may be shortened by two-thirds, success rates may dramatically increase, and clinical trial costs could be cut substantially. New computer based technologies will create a greater understanding of the biology of disease and the evolution of ‘Virtual man’ to enable researchers to predict the effects of new drug candidates before they enter human beings.
Pharma 2020: The vision: Which path will you take?
But Pharma 2020: The Vision - Which Path Will You Take? indicates that the current pharmaceutical industry business model is both economically unsustainable and operationally incapable of acting quickly enough to produce the types of innovative treatments demanded by global markets. In order to make the most of these future growth opportunities, the industry must fundamentally change the way it operates.
*K dispozici v anglických originálech
Kontakty
Buďte s námi v obraze
